Short report

Homovanilic acid in Huntington's disease and Sydenham's chorea

L CUNHA, C R OLIVEIRA, M DINIZ, R AMARAL,
A F CONÇALVES, AND J PIO-ABREU

From the Clínica Neurológica, Hospitais da Universidade de Coimbra, Coimbra

SUMMARY Homovanilic acid (HVA) was determined in the lumbar CSF of 12 patients with Huntington's disease and 12 with Sydenham's chorea before and after probenecid administration. The means of HVA concentration (basal and after probenecid) were lower in those with Huntington's disease than in controls, and were even lower in a sub-group characterised by increased tone and slowness of voluntary movement. There was no correlation between CSF HVA values and the severity of abnormal movements, nor with length of the illness and age of the patients with Huntington's disease. The mean basal HVA concentration did not differ from controls in those with Sydenham's chorea but the accumulation with probenecid was significantly lower. These results suggest a decrease in cerebral dopamine release in both forms of chorea.

About one third of the homovanilic acid (HVA) derived from the catabolism of dopamine (DA) and released in the striatum enters the CSF in the lateral ventricle.^{1 2} There is some evidence to suggest that the concentration of this acid metabolite in ventricular CSF, is related to the concentration in the striatum.²⁻⁴ But the concentration of HVA cisternal and lumbar CSF is lower, and the correlation with striatal levels disappears.^{1 5 6} At least three mechanisms are responsible for the lower HVA levels-lumbar CSF (1) the diffusion of the HVA "jet," (2) the CSF circulation, (3) an active transport mechanism localised in the fourth ventricle and sub-arachnoid space.⁷⁻⁸ This active transport mechanism can be blocked with probenecid, which prevents the efflux of HVA and 5-HIAA from CSF.⁸⁻¹¹ There has been considerable variation in the dose and timing of probenecid administration to man.¹²⁻¹⁵

Various groups of patients with Huntington's disease have been reported to have decreased or low normal concentrations of HVA in the CSF,¹⁶⁻²¹ although other authors have found values similar to controls.²²⁻²³ Some papers have reported on small number of cases, with a great variability of values.²⁴⁻²⁵ A very low basal HVA

level was described by Curzon¹⁶ in two patients with severe akinetic-rigid Huntington's disease. The increment of CSF HVA after probenecid was reported as normal in two patients,²⁶ but decreased in two other papers reporting groups of eight and two patients respectively with Huntington's disease.^{18 27}

There is little information available on the concentrations of CSF HVA in Sydenham's chorea, but again values within the range of normal have been reported.^{16 29}

We have studied two groups of patients, 12 with Sydenham's chorea and 12 with Huntington's disease. CSF HVA was determined before and after probenecid administration. Correlations with clinical data were made.

Material and methods

The main features of the Huntington's disease and Sydenham's chorea patients are summarised in tables 1 and 2. Severity of abnormal movements was assessed by the AIM scale (maximum 42) and the criteria for gradation of rigidity and bradykinesia were those defined by Duvoisin.³⁰ None of the patients was taking any drug for at least three weeks before determination of CSF HVA. The nature of the investigation was explained to the patient or to a responsible relative and consent was obtained. Three days before the lumbar puncture the patient was kept on a diet that excluded all the foods known to influence monoaminergic metabolism.

Address for reprint requests: Dr L Cunha, Clínica Neurológica, Hospitais da Universidade de Coimbra, Coimbra, Portugal.

Accepted 25 September 1980

Table 1 Huntington's disease

Sex	Age	Family history	Severity of ab movements	Rigidity	Bradykinesia	Dementia	Basal HVA (ng/ml)	Post-probenecid HVA (ng/ml)
M	43	+	10	2	2	+	26	52
M	46	+	28	0	0	+++	—	62
F	57	+	36	0	0	+++	—	115
F	43	+	22	2	2	++	16	32
M	33	+	15	0	0	+	28	158
M	44	+	20	0	0	++	63	66
M	48	+	32	0	0	++	47	91
F	61	+	18	2	1	+	11	13
F	38	+	12	2	2	+	19	—
F	41	+	31	0	0	+	38	113
F	47	+	38	0	0	++++	8	36
M	43	+	24	2	2	+++	11	21
$\bar{x} \pm 1$ SD							26.7 $\pm$ 17.0	69.0 $\pm$ 43.4
Control							53.6 $\pm$ 38.9	136.2 $\pm$ 35.0

In ten Huntington's and nine Sydenham's chorea patients a lumbar puncture was done to determine basal HVA values. In eleven patients with Huntington's disease 6 g of probenecid were given in three doses at three hours intervals and a lumbar puncture was done three hours after the last dose. A similar procedure was done on ten Sydenham's chorea patients, with the total dosage of probenecid of 90 mg/kg. Nine patients with Huntington's disease and seven with Sydenham's chorea had CSF HVA determinations before and after probenecid. The samples of the first 5 ml of CSF were stored at -20°C until determination of HVA by the method of Gerbode and Bowers.³¹ Sixteen patients with neurological or psychiatric disorders not known to disturb monoaminergic metabolism or CSF dynamics were used as controls (basal HVA value 53.6 ± 38.9 ng/ml; post-probenecid HVA value 136.2 ± 35 ng/ml (mean ± 1 SD).

Results

The data are summarised in tables 1 and 2. The mean CSF HVA in the patients with Huntington's

disease after probenecid was less than in controls ($p < 0.001$). There also was a reduction of the mean increment, but it did not reach statistical significance. In general, those patients with Huntington's disease in whom rigidity and slowness of movement were detected had mean post-probenecid concentration less than those in the group on which those symptoms were not present. No correlation was found between HVA values and severity of abnormal movements, nor with length of history or age of the patients with Huntington's disease. The mean basal value in Sydenham's chorea did not differ from controls, but there was a smaller increment with probenecid administration, so that the post-probenecid level was less than that in controls ($p < 0.005$).

Discussion

There is some difference of opinion over the findings of different authors regarding concentrations of striatal DA in Huntington's disease. Ehringer and Hornykiewicz^{32 33} originally found values similar to controls, but subsequently a decrease in striatal DA has been reported.³⁴⁻³⁶ Spokes,³⁷ in a recent paper, found an increase of DA concentration per mg of tissue, but the concentration tended to be less in rigid chorea.

The variability of values found for DA concentration in the striatum may be one of the factors to explain the variability of findings on CSF HVA in Huntington's disease, but the reduction in CSF HVA, especially after probenecid, seems to imply a reduction of cerebral DA release, particularly in those with increased tone and slowness of movement. This latter group of patients with Huntington's disease with a decreased accumulation of HVA, also has been

Table 2 Sydenham's chorea

Age	Sex	Basal value (ng/ml)	Post-probenecid value (ng/ml)
12	F	36	48
12	F	48	71
22	F	—	66
13	F	52	—
11	M	—	131
12	M	85	91
9	F	24	37
10	F	48	92
8	M	21	124
11	M	33	100
13	M	32	—
14	F	—	40
$\bar{x} \pm 1$ SD		42.1 $\pm$ 18.3	80.0 $\pm$ 31.5
Control		53.6 $\pm$ 38.9	136.2 $\pm$ 35.0

reported to exhibit an increased incidence of paranoid psychosis.³⁸ However, there was no correlation of CSF HVA with the severity of abnormal movements suggesting that factors other than DA metabolism, including alteration of other neurotransmitters, such as acetylcholine and γ -aminobutyric acid and substance P, may be responsible for the severity of chorea.³⁹⁻⁴²

In Sydenham's chorea, a fast disappearing disease, the reduction of accumulation of HVA after probenecid again suggests a decrease in DA turnover.

References

- 1 Sourkes TL. Enzymology and sites of action of monoamines in the central nervous system. *Advances in Neurology* 1973; **2**:13-36. New York: Raven Press.
- 2 Wightman RM, Strope E, Plotsky P, Adams RN. In vivo voltammetry: monitoring of Dopamine metabolites in CSF following release by electrical stimulation. *Brain Res* 1978; **159**:55-68.
- 3 Guldberg HC. Changes in amine metabolite concentrations in cerebrospinal fluid as an index of turnover. In: *Metabolism of Amines in the Brain*, G Hooper ed. London: MacMillan, 1969; 55-64.
- 4 Moir ATB, Ashcroft GW, Crawford TBB, Eccleston D, Guldberg HC. Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. *Brain* 1970; **93**:357-68.
- 5 Garelis E, Sourkes TL. Sites of origin in the central nervous system of monoamine metabolites measured in cerebrospinal fluid. *J Neurol Neurosurg Psychiatry* 1973; **36**:625-9.
- 6 Roos BE. Metabolites of the monoamines in the cerebrospinal fluid (CSF). *Monoamines, Noyaux Gris Centraux et Syndrome de Parkinson*, ed J de Ajuriaguere, Paris: Masson et Cie, 1971; 119-28.
- 7 Ashcroft GK, Dow RC Moir ATB. The active transport of 5-hydroxyindol-3-ylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid from a recirculatory perfusion system of the cerebral ventricles of the unanaesthetized dog. *J Physiol (Lond)* 1968; **199**:397-425.
- 8 Wolfson LI, Katzman R, Escrivá A. Clearance of amine metabolites from the cerebrospinal fluid: The brain as a "sink". *Neurology* 1978; **24**:772-9.
- 9 Guldberg HC, Ashcroft GW, Crawford TBB. Concentrations of 5-Hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with Probenecid. *Life Sciences* 1966; **5**:1570-5.
- 10 Forn J. Active transport of 5-Hydroxyindoleacetic acid by the rabbit choroid plexus in vitro. Blockade by Probenecid and metabolic inhibitors. *Biochem Pharmacol* 1972; **21**:619-24.
- 11 Aizenstein ML, Korf J. Aspects of influx and efflux of HVA of rat CSF. *Brain Res* 1978; **149**:129-40.
- 12 Lakke JPWF, Korf J, Van Praag HM. Clinical significance of Probenecid test. *Lancet* 1973; **1**: 614-5.
- 13 Perel JM, Levitt M, Dumner DL. Plasma and cerebrospinal fluid. Probenecid concentration as related to accumulation of acidic biogenic metabolism in man. *Fed Proc* 1973; **32**:619(Abst 2724).
- 14 Shaywitz BA, Comen DJ, Bowers MB Jr. Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. *Neurology* 1975; **25**:72-9.
- 15 Kartzinel R, Ebert MH, Chase TN. Intravenous Probenecid loading. Effects on plasma and cerebrospinal fluid Probenecid levels and on monoamine metabolites in cerebrospinal fluid. *Neurology* 1976; **26**:992-6.
- 16 Curzon G. Involuntary movements other than Parkinsonism: Biochemical aspects. *Proc Roy Soc Med* 1973; **66**:873-6.
- 17 Curzon G, Gumpert EJW, Sharp DM. Amine metabolites in the cerebrospinal fluid in Huntington's chorea. *J Neurol Neurosurg Psychiatry* 1972; **35**:514-9.
- 18 Chase TN. Biochemical and pharmacologic studies of monoamines in Huntington's chorea. *Advances in Neurology* 1973; **1**:533-41. New York: Raven Press.
- 19 Bernheimer M, Birkmayer W, Hornykiewicz O. Homovanillinsäure in liquor cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS. *Wein Klin Wochenschr* 1966; **78**:417-9.
- 20 Aquilonius SM, Sjostrom R. Colinergeric and dopaminergic mechanisms in Huntington's chorea. *Life Sciences*, Part 1, 1971; **10**:405-14.
- 21 Caraceni T, Calderini T, Consolazione A et al. Biochemical aspects of Huntington's chorea. *J Neurol Neurosurg Psychiatry* 1971; **40**:581-7.
- 22 Klawans HL Jr. Cerebrospinal fluid homovanillic acid in Huntington's chorea. *J Neurol Sci* 1971; **13**:277-9.
- 23 Davidson DLW, Yates CM, Mawdsley C, Pullar IA, Wilson H. CSF studies on the relationship between Dopamine and 5-Hydroxytryptamine in parkinsonism and other movement disorders. *J Neurol Neurosurg Psychiatry* 1977; **40**:1136-41.
- 24 Schenk G, Leijnse-Ybema HJ. Huntington's chorea and Levodopa. *Lancet* 1974; **1**:364.
- 25 Loeb C, Roccatagliata G, La Medica G, Abbruzzese G, Albano C. Levodopa and Huntington's chorea. *J Neurol Neurosurg Psychiatry* 1976; **39**:958-61.
- 26 Lal S, De la Vega CE, Garelis E, Sourkes TL. Apomorphine, pimozone, L-DOPA and the probenecid test in Huntington's chorea. *Psychiat Neurol Neurochir* 1973; **72**, 2, 113-7.
- 27 Bachman DS, Butler IJ, Mckhann GM. Long-term treatment of juvenile Huntington's chorea

- with dipropilacetic acid. *Neurology* 1977; **27**: 193-7.
- 28 Lakke JPWF, Nienhuis RJ, Schut T, Korf J. The probenecid test and the effect of L-DOPA treatment: clinical application of the probenecid test and its limitation in disorders of the basal ganglia. *Current Concepts in the Treatment of Parkinsonism*, MD Yahr. New York: Raven Press, 1974; 37-60.
 - 29 Klawans Jr HL. The pharmacology of extrapyramidal movement disorders. *Monographs in Neurol Sciences*, Maynard M Cohen ed, 1973.
 - 30 Duvoisin RC. The evaluation of extrapyramidal disease. *Monoamines noyaux gris centraux et syndrome de Parkinson*, J de Ajuriaguierre ed. Paris: Masson et Cie, 1971; 313-26.
 - 31 Gerbode FA, Bowers MB. Measurement of acid monoamine metabolites in human and animal cerebrospinal fluid. *J Neurochemistry* 1968; **15**: 1053-5.
 - 32 Ehringer H, Hornykewicz O. Verteilung von Noradrenalin und Dopamine (3-Hydroxytyramine) in Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen system. *Klin Wschr* 1960; **38**: 1236.
 - 33 Hornykewicz O. Dopamine (3-Hydroxytyramine) and brain function. *Pharmacol Rev* 1966; **18**: 925-64.
 - 34 Bernheimer H, Jellinger K, Seitelberger F. Brain dopamine and the Syndromes of Parkinson and Huntington—clinical, morphological and neurochemical correlations. *J Neurol Sci* 1973; **20**: 415-32.
 - 35 Bird ED, Iverson LL. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. *Brain* 1974; **97**: 457-72.
 - 36 Hornykewicz O. Neurohumoral interactions and basal ganglia function and dysfunction. *The basal ganglia*, MD Yahr ed. New York: Raven Press, 1976: 269-78.
 - 37 Spokes EGS. Dopamine in Huntington's disease: A study of postmortem brain tissue. *Advances in Neurology*, vol 23, New York: Raven Press, 1979; 481-93.
 - 38 Pio Abreu JL, Cunha L, Oliveira CR *et al.* Dopamina, movimentos anormais e sintomas psiquiátricos. *Psiquiatria Clinica* (in press) 1980.
 - 39 Aquilonius SM, Eckernas SA, Sundwall A. Regional distribution of choline acetyl-transferase in the human brain; changes in Huntington's chorea. *J Neurol Neurosurg Psychiatry* 1975; **38**: 669-77.
 - 40 McGeer PL, McGeer EG, Fibigier HC. Choline acetylase and glutamic acid decarboxilase in Huntington's chorea. A preliminary study. *Neurology* 1973; **23**: 912-7.
 - 41 Perry T, Hansen S, Kloster M. Huntington's chorea. Deficiency of -aminobutyric acid. *New Engl J Med* 1973; **288**: 337-43.
 - 42 Kanazawa JE, Bird E, O'Conel R, Powell. Evidence for a decrease in substance content of substantia nigra in Huntington's chorea. *Brain Res* 1977; **120**: 387-92.